IL17A and rheumatoid arthritis: In light of these cell mechanisms, macrophages represent useful therapeutic early targets to restrain subsequent pathogenic cell activation, including that of Th17, which infiltrate synovial tissue of RA patients and produce IL-17, a RANKL-inducer cytokine (Kotake et al., 1999; Nakae et al., 2003).